Huahai Pharmaceutical disclosed an earnings forecast on October 7, expecting net profit attributable to shareholders of the listed company for the first three quarters of 2026 to be between 1.028 billion yuan and 1.103 billion yuan, up 170% to 190% year on year. The company said that during the reporting period, sales revenue from its active pharmaceutical ingredients business grew substantially year on year, its domestic finished drug business added 12 products selected in centralized procurement to achieve incremental expansion, its US finished drug business turned from loss to profit year on year, it received related fees after winning the European arbitration over valsartan, and reduced research and development expenses, among other factors, jointly drove the increase in profit.
Zhejiang Huahai Pharmaceutical Co LtdEarnings forecast expects net profit for first three quarters of 2026 to rise 170%-190% year on year.
